Molnupiravir-drug-e1623323286699.jpg

GCAP GENERIC DRUG FOR COVID-19

Molnupiravir (Lagevrio) is the first-ever investigational oral antiviral therapy for the treatment of SARS-CoV-2 (COVID-19) in non-hospitalized adult patients. It is a potent ribonucleoside analog that blocks SARS-CoV-2 replication by acting as a competitive substrate of virally-encoded RNA-dependent RNA polymerase.

GCAP Molnupiravir Package.jpeg

DRUG INFORMATION

Molnupiravir

Coming Soon

FACTORY INFORMATION

COMING SOON

ZqvaR7I2eDd0_FZYFu0DVDAwjtycEgvmp2I4z0nwByU2L6qsiUaa9p3Bco0sJDqyDqatLBnrAzv5fCs5cVbics6m1A

INQUIRY

Get Started Now

Thanks for submitting!

Trees From Above